NASDAQ · Biotechnology

VTGN (VTGN) Stock

$0.24 -1.33% NASDAQ: VTGN Healthcare

Valuation

MetricValue
Price$0.24
Market Cap$9.76M
P/E Ratio-0.61
P/B Ratio0.47
P/S Ratio24.88
EPS (TTM)$-1.13
52-Week High$5.14
52-Week Low$0.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-101.55%
ROA-55.53%
ROCE-80.00%
Gross Margin54.68%
Operating Margin-88.48%
Net Margin-84.87%
Debt/Equity0.03
Current Ratio6.31

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$1.0M$0
Operating Profit$-18.0M$-48.0M$-59.0M$-33.0M$-56.0M
Net Profit$-18.0M$-48.0M$-59.0M$-29.0M$-51.0M
EPS$-14.74$-7.38$-8.51$-1.52$-1.67
Op Margin-1646.1%-4308.7%26109.3%-3103.5%-11517.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$108.0M$75.0M$21.0M$124.0M$84.0M
Total Liabilities$16.0M$10.0M$9.0M$9.0M$14.0M
Cash$103.0M$68.0M$17.0M$119.0M$67.0M
Borrowings$4.0M$3.0M$3.0M$2.0M$2.0M

Latest News

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? Insider Monkey · Jul 15, 2026 Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire · Jun 30, 2026 Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update Business Wire · Jun 15, 2026 Vistagen Therapeutics Says Fasedienol Clinical Program Exceeds ICH Exposure Thresholds MT Newswires · Jun 10, 2026 Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder Business Wire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-12.0M$-45.0M$-50.0M$-26.0M$-42.0M
Investing Cash Flow$-1.0M$0$-1.0M$0$-13.0M
Financing Cash Flow$5.0M$951.0M$0$0$0
Net Cash Flow$102.0M$-35.0M$-51.0M$103.0M$-52.0M
Free Cash Flow$-12.0M$-45.0M$-50.0M$-26.0M$-42.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA0.54
FCF Yield-307.58%
Quick Ratio4.67
Interest Coverage—
Return 1Y-88.94%
Return 3Y-85.94%
Return 5Y-99.70%

Ownership

Insiders Held0.29%
Institutions Held40.81%
Institutions Float Held40.93%
Institutional HolderSharesReport Date
Orbimed Advisors LLC.3,060,0002026-03-31
TCG Crossover Management, LLC2,676,5802026-03-31
Vanguard Capital Management LLC1,574,2002026-03-31
Adar1 Capital Management, LLC 751,1412026-03-31
Stempoint Capital LP 616,7492026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ABOS $2.27 -0.66% -1.17 $163.60M 0.00%
ACTU $1.09 -5.22% -2.73 $26.08M 0.00%
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
HURA $2.09 -2.34% -3.75 $133.10M 0.00%

About VTGN

VTGN is led by CEO Shawn K. Singh, employs 48 people, headquartered in US, publicly traded since 2011.

VTGN stock trades at $0.24 with a market capitalization of $9.76M. The stock is valued at a price-to-earnings (P/E) ratio of -0.61, price-to-book of 0.47, price-to-sales of 24.88. Over the past 52 weeks the stock has ranged between $0.21 and $5.14, and currently trades 95.3% below its 52-week high.

On profitability, VTGN generates a return on equity (ROE) of -101.55%, return on capital employed of -80.00%, an operating margin of -88.48%, a net profit margin of -84.87%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides